Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jee Hyun | - |
dc.contributor.author | Cho, Hye Kyung | - |
dc.contributor.author | Kim, Ki Hwan | - |
dc.contributor.author | Lee, Jina | - |
dc.contributor.author | Kim, Yae-Jean | - |
dc.contributor.author | Eun, Byung Wook | - |
dc.contributor.author | Kim, Nam Hee | - |
dc.contributor.author | Kim, Dong Ho | - |
dc.contributor.author | Jo, Dae Sun | - |
dc.contributor.author | Kim, Hwang Min | - |
dc.contributor.author | Kim, Yun-Kyung | - |
dc.date.accessioned | 2021-08-31T22:06:35Z | - |
dc.date.available | 2021-08-31T22:06:35Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-12-02 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/60963 | - |
dc.description.abstract | Background: The titer of influenza vaccine-induced antibodies declines over time, and younger children have lower immunogenicity and shorter duration of immunity. This study aimed to compare persistence of antibody at 6 months after influenza vaccination according to influenza virus strains, vaccine type, antigen dose, and primed status in children aged 6 to 35 months. Methods: A total 124 healthy children aged 6 to 35 months were enrolled from September to December 2016 at 10 hospitals in Korea and randomly assigned to either a full dose of quadrivalent influenza vaccine or a half dose of trivalent influenza vaccine with Victoria B strain group. Hemagglutination inhibition antibody titers (that measure the seroprotection rates) were assessed for the recommended influenza strains at 6 months post vaccination. Results: The seroprotection rates at 6 months for strains A (H1N1), A (H3N2), B/Yamagata, and B/Victoria were 88.7%, 97.4%, 36.6%, and 27.6%, respectively. The seroprotection rates for A (H1N1), A (H3N2) and B (Victoria) were 91.4%, 98.7% and 27.5% in a full dose of quadrivalent vaccine vs. 83.7%, 94.6% and 27.9% in a half dose trivalent vaccine, respectively. The seroprotection rate for the B (Yamagata) strain was 23.8% in the quadrivalent group and 14.0 0 % in the trivalent group. Conclusion: Persistence of antibodies at 6 months was more favorable against the influenza A strains than against the B strains. Persistence of antibodies to additional B strain at 6 months was superior in the quadrivalent vaccine group. The immunity of primed children with different B strains was not superior to that of the unprimed group with another B strain. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | YOUNG-CHILDREN | - |
dc.subject | ANTIBODY PERSISTENCE | - |
dc.subject | IMMUNOGENICITY | - |
dc.subject | SAFETY | - |
dc.subject | EFFICACY | - |
dc.subject | SEASON | - |
dc.title | Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Yun-Kyung | - |
dc.identifier.doi | 10.3346/jkms.2019.34.e279 | - |
dc.identifier.scopusid | 2-s2.0-85075789075 | - |
dc.identifier.wosid | 000500383300001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.34, no.46 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 34 | - |
dc.citation.number | 46 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | YOUNG-CHILDREN | - |
dc.subject.keywordPlus | ANTIBODY PERSISTENCE | - |
dc.subject.keywordPlus | IMMUNOGENICITY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SEASON | - |
dc.subject.keywordAuthor | Quadrivalent Influenza Vaccine | - |
dc.subject.keywordAuthor | Trivalent Influenza Vaccine | - |
dc.subject.keywordAuthor | Immunity | - |
dc.subject.keywordAuthor | Hemagglutination | - |
dc.subject.keywordAuthor | Children | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.